Stock Analysis
Abbott Laboratories (ABT) Stock Analysis
Abbott Laboratories (ABT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Abbott Laboratories (ABT) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 74/100. Value is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ABT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $106.20 |
| AIQ Score | 59/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $179.44B |
| P/E Ratio (TTM) | 38.41 |
| Forward P/E | — |
| EPS (quarter ended 2026-09-30) | $0.53 |
| Revenue (quarter ended 2026-09-30) | $13.01B |
| Dividend Yield (TTM) | 2.43% |
| Beta | 0.58 |
| Volume | 8.44M |
| 52-week range | $81.97-$132.03 |
| RSI 14 | 63.65 |
| 50-Day SMA | $104.50 |
| 200-Day SMA | $101.79 |
| Analyst Price Target | $122.27 |
| Next Earnings | Jan 28, 2027 |
ABTAbbott Laboratories
Healthcare / Medical - Devices
Low Priority
Above Peers
Latest quote
- Momentum74
- Value51
- Quality55
- Risk resilience57
- Sentiment—
ABT Stock Analysis Summary
Abbott Laboratories (ABT) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 74/100. Value is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ABT has AIQ Score of 59/100 with Momentum base of 74/100 and fading Value at 51/100. Wait for component alignment before adding exposure.
Momentum (74/100) leads while Value (51/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.56% stock move · ABT classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ABT Bullish or Bearish Right Now?
ABT currently has a neutral overall setup. Momentum is the strongest factor at 74/100, while Value is weakest at 51/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 74/100.
- - Price is +0.07% above its 50-day SMA.
- - Analyst target implies +15.13% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (33 vs 4).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
ABT's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 8 neutral, and 4 sell votes. ABT's 14-day RSI is 63.65, which places the stock in a constructive momentum range. ABT's beta is 0.58, indicating lower market sensitivity than the broad market.
What Changed in ABT?
The largest recent change in ABT is Momentum moving up by 13.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the ABT Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ABT Decision Framework
Public evidence layers, setup checks, and risk context for Abbott Laboratories.
Abbott Laboratories (ABT) Stock Analysis
Abbott Laboratories has an AIQ Score of 59/100 in a Neutral regime. Momentum is strongest at 74/100. Beta is 0.58, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ABT is in a Neutral AIQ regime with score 59/100. |
| Signal Conflict | The primary conflict is that momentum leads at 74/100 while value lags at 51/100. |
| Factor Evidence | Momentum 74/100 · Value 51/100 · Quality 55/100 · Risk 57/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 74/100.
Momentum is 74/100 and RSI (14) is 63.6.
ABT is in a Neutral regime at 59/100.
Risk factor is 57/100 with beta 0.58 and annual volatility 27.34%.
Current conflict: momentum leads at 74/100 while value lags at 51/100.
ABT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ABT Fundamentals
ABT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ABT Technical Analysis
ABT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ABT Stock Catalysts
Track ABT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ABT Dividend Analysis
ABT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ABT Financial Data
ABT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ABT Risk Analysis
ABT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ABT Stock News
ABT stock news, market tone, recent headlines, and catalyst context.
ABT vs Medical Devices Peers
Current peer cohort: ABT · ALGN · AVTR · BAX · BDX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ABT Current stock | 59/100 | 51/100 | 74/100 | 57/100 | -0.65 | 27.34% | Current |
| ALGN Align Technology | 67/100 | 62/100 | 76/100 | 57/100 | 0.49 | 39.27% | ABT vs ALGN |
| AVTR Avantor | 57/100 | 63/100 | 75/100 | 62/100 | 0.96 | 43.75% | ABT vs AVTR |
| BAX Baxter International | 44/100 | 69/100 | 43/100 | 46/100 | 0.24 | 43.98% | ABT vs BAX |
| BDX Becton Dickinson | 59/100 | 63/100 | 80/100 | 49/100 | 0.32 | 30.97% | ABT vs BDX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ABT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ABT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ABT Stock FAQ
What is ABT stock price today?
Abbott Laboratories's current stock price is $106.20. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ABT bullish or bearish right now?
ABT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ABT's market cap?
ABT's market cap is $179.44B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ABT's current P/E ratio?
ABT's current P/E ratio is 38.41 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ABT's RSI?
ABT's 14-day RSI is 63.65 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ABT above its 50-day and 200-day moving averages?
ABT is 0.07% from its 50-day SMA and 2.73% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ABT's next earnings date?
ABT's next earnings date is currently listed as Jan 28, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ABT pay a dividend?
ABT's dividend yield is 2.43% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.